Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - PsA Disease Activity Chandran Lab

ABSTRACT: Classifying Patients with Psoriatic Arthritis According to their Disease Activity Status using Serum Metabolites and Machine Learning

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Vinod Chandran

PROVIDER: MSV000092699 | GNPS | Sat Aug 19 17:34:00 GMT+01:00 2023

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PsA Disease Activity Chandran Lab

Project description:Classifying Patients with Psoriatic Arthritis According to their Disease Activity Status using Serum Metabolites and Machine Learning

2023-08-19 | MSV000092699 | MassIVE

Prediction of Breast Cancer Estrogen Receptor Status using Machine Learning

Project description:Gene expression profiles were generated from 199 primary breast cancer patients. Samples 1-176 were used in another study, GEO Series GSE22820, and form the training data set in this study. Sample numbers 200-222 form a validation set. This data is used to model a machine learning classifier for Estrogen Receptor Status. RNA was isolated from 199 primary breast cancer patients. A machine learning classifier was built to predict ER status using only three gene features.

2013-01-01 | E-GEOD-29210 | biostudies-arrayexpress

Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in patients with Psoriatic Arthritis

Project description:This dataset contains .RAW files acquired for the paper: Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in patients with Psoriatic Arthritis.

| MSV000092967 | MassIVE

GNPS - Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in patients with Psoriatic Arthritis

Project description:This dataset contains .RAW files acquired for the paper: Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in patients with Psoriatic Arthritis.

| MSV000092967 | GNPS

Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment

Project description:Background: We and others have previously demonstrated the potential for circulating exosome microRNAs to aid in disease diagnosis. In this study, we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy. We studied patients with relapsing-remitting multiple sclerosis prior to and 6 months after treatment with fingolimod. Methods: Disease activity was determined using gadolinium-enhanced magnetic resonance imaging. Serum exosome microRNAs were profiled using next-generation sequencing. Data were analysed using univariate/multivariate modelling and machine learning to determine microRNA signatures with predictive utility. Results: we identified 15 individual miRNAs that were differentially expressed in serum exosomes from post-treatment patients with active versus quiescent disease. The targets of these microRNAs clustered in ontologies related to the immune and nervous systems, and signal transduction. While the power of individual microRNAs to predict disease status post-fingolimod was modest (average 77%, range 65 to 91%), several combinations of 2 or 3 miRNAs were able to distinguish active from quiescent disease with greater than 90% accuracy. Further stratification of patients identified additional microRNAs associated with stable remission, and a positive response to fingolimod in patients with active disease prior to treatment. Conclusions: Overall, these data underscore the value of serum exosome microRNA signatures as non-invasive biomarkers of disease in multiple sclerosis and suggest they may be used to predict response to fingolimod in future clinical practice. Additionally, these data suggest that fingolimod may have mechanisms of action beyond its known functions.

2019-11-08 | GSE140106 | GEO

Adults with Systemic Lupus Exhibit Distinct Molecular Phenotypes Associated with Clinical Disease Activity

Project description:Background: The clinical and pathologic diversity of systemic lupus erythematosus (SLE) has hindered diagnosis, management, and treatment development. This study clustered adult SLE patients through comprehensive molecular phenotyping to improve distinctions with prognostic and therapeutic relevance. Methods: Plasma, serum, and RNA were collected from 198 adult SLE patients. Disease activity was scored by modified SELENA-SLEDAI. Twenty-nine co-expression module scores were calculated from microarray gene-expression data. Plasma soluble mediators (n=23) and autoantibodies (n=13) were assessed by multiplex bead-based assays and ELISAs. Phenotypic patient clusters were identified by machine learning combining K-means clustering and random forest analysis of co-expression module scores and soluble mediators. Findings: SLEDAI scores correlated strongly with interferon module scores, more modestly with plasma cell and select cell cycle modules, and with circulating IFNα, IL21, IL1α, IL17A, IP10, and MIG levels. Co-expression modules and soluble mediators differentiated seven clusters of SLE patients with unique molecular phenotypes. Inflammation and interferon modules were elevated in Clusters 1 (moderately) and 4 (strongly), with decreased T cell modules in Cluster 4. The other clusters differed in monocyte, neutrophil, plasmablast, B cell, and T cell modules. Clusters 1 and 4 had higher SLEDAI scores, and more frequent anti-dsDNA, low complement, and renal activity. These features were also prominent in Cluster 3, which lacked the interferon and inflammation signatures. Arthritis and rashes were common in all clusters. Interpretation: Molecular profiles can distinguish SLE subsets. Prospective longitudinal studies of these profiles may help to improve prognostic evaluation, clinical trial design, and precision medicine approaches.

2020-03-16 | GSE138458 | GEO

Machine learning-based prediction of the activity and specificity of Cas9 variants in gene editing

Project description:Machine learning-based prediction of the activity and specificity of Cas9 variants in gene editing

2024-08-22 | GSE231840 | GEO

Inflammatory Cytokines shape a Changing DNA Methylome in Monocytes Mirroring Disease Activity in Rheumatoid Arthritis (patients)

Project description:Genome wide DNA methylation profiling of monocytes from healthy donors and rheumatoid arthritis patients. The Illumina Infinium MethylationEPIC Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpGs in CD11b+CD33+CD15neg monocytes isolated from PBMCs of 17 healthy donors and 47 rheumatoid arthritis patients with different disease activity scores (DAS28).

2019-12-31 | GSE134429 | GEO

Multi-omics and Machine Learning Accurately Predicts Clinical Response to Adalimumab and Etanercept Therapy in Patients with Rheumatoid Arthritis [RNA-Seq]

Project description:Objectives: To predict response prior to anti-TNF treatment and comprehensively understand the mechanism how patients respond differently to anti-TNF treatment in rheumatoid arthritis (RA). Methods: Gene expression and/or DNA methylation profiling on PBMC, monocytes, and CD4+ T cells, from 80 RA patients before initiating either adalimumab (ADA) or etanercept (ETN) therapy was studied. After 6-month treatment response was evaluated according to the EULAR criteria of disease response. Differential expression and methylation analyses were performed to identify the response-associated transcriptional and epigenetic signatures. Machine learning models were built using these signatures by random forest algorithm to predict response prior to anti-TNF treatment and were further validated by a follow-up study. Results: Transcriptional signatures in ADA and ETN responders are divergent in PBMCs, and this phenomenon was reproduced in monocytes and CD4+ T cells. The genes upregulated in CD4+ T cells of ADA responders were enriched in the TNF signaling pathway, while very few pathways were differential in monocytes. Differential methylation positions (DMPs) of responders to ETN but not to ADA are majorly hypermethylated. The machine learning models to predict the response to ADA and ETN using differential genes reached overall accuracy of 85.9% and 79%, respectively. The models using DMPs reached overall accuracy of 84.7% and 88% for ADA and ETN, respectively. A follow-up study validated the high performance of these models. Conclusions: Machine learning models based on these molecular signatures could accurately predict response before ADA and ETN treatment, paving the path towards personalized anti-TNF treatment.

2020-08-24 | GSE138746 | GEO

Multi-omics and Machine Learning Accurately Predicts Clinical Response to Adalimumab and Etanercept Therapy in Patients with Rheumatoid Arthritis [Methylation array]

2020-08-24 | GSE138653 | GEO